UNITED KINGDOM; UNITED STATES OF AMERICA —Global biopharmaceutical company GSK plc has entered into a definitive agreement to acquire the global development and commercial rights to a novel trispecific T cell-engager asset from Chimagen Biosciences. Under the financial terms, GSK will pay an upfront license fee and up to USD 750 million in cumulative success-based development and commercial milestone payments. The asset targets multiple myeloma treatment, with Phase I clinical trials scheduled to initiate in 2027. The transaction remains subject to customary regulatory approvals and closing conditions.
GSK plc is a London-headquartered multinational pharmaceutical and biotechnology enterprise focused on developing vaccines, oncology treatments, and immunology therapeutics. Chimagen Biosciences is a privately held biotechnology firm specializing in engineering multi-specific antibody candidates for oncology and autoimmune indications.
The acquisition expands GSK's existing hematological oncology platform by introducing a next-generation cell engager designed to simultaneously bind T cells and two tumor-associated antigens. Traditional T cell-engager therapies demonstrate efficacy in treating plasma cell malignancies but face operational hurdles due to adverse tolerability profiles. By engineering dual tumor-antigen targeting capabilities, the trispecific construct aims to deliver enhanced therapeutic durability and lower toxicity, facilitating broader adoption in earlier-line treatment settings for relapse-prone blood cancers.
This deal underscores intense commercial focus on the US multiple myeloma market, which is projected to surpass USD 10 billion by 2032. For the wider biotechnology sector, early-stage asset licensing transactions demonstrate ongoing pharmaceutical demand for targeted multi-specific antibody platforms. The transaction reinforces licensing momentum between global pharmaceutical majors and specialized discovery startups, providing capital for early-stage pipeline monetization while expanding clinical development portfolios across international markets.
